Cross-Sector entity

Jane Street Group LLC

Company
5

Of the tracked stories, 5 of 8 also mention Weiss Ratings, the most common co-covered peer. Coverage clusters in earnings, which accounts for 2 of those 8, with the remainder spread across 6 other categories. 0% of these stories carry negative sentiment.

8 verified stories tracked

Last mentioned: Aug 17, 2026

RSS updates
Share

Entity pulse

Recent coverage · Jane Street Group LLC

↑
8 stories
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Jane Street Group LLC

Of the tracked stories, 5 of 8 also mention Weiss Ratings, the most common co-covered peer. Coverage clusters in earnings, which accounts for 2 of those 8, with the remainder spread across 6 other categories. 0% of these stories carry negative sentiment. The tracked stories average 2 original sources each. We currently track 8 Cross-Sector stories that mention Jane Street Group LLC, published between August 12, 2026 and August 17, 2026.

Stories tracked
8
Negative
0%
Sources per story
2

Computed from the 8 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Jane Street Group LLC. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. STE trading level

    STERIS shares opened at $232.88, within a 52-week range of $195.14 to $269.44.

  2. Q2 earnings released; EPS beats consensus

    Company reported ($1.40) EPS versus ($1.55) consensus; shares rose $0.05 to $0.57 on 2.3x average volume

  3. Weiss Ratings reiterates Sell

    Restated a 'sell (e+)' rating on MBRX shares in a research note

  4. Director Breeden insider sale

    STERIS director Richard C. Breeden sold 1,481 shares at an average price of $209.51, totaling $310,284.31 — a 3.66% reduction leaving 38,964 shares directly owned.

  5. Q2 2026 new positions

    Stoneridge Investment Partners initiated a new 4,497-share stake valued at $1,027,000. Elevation Wealth Partners raised its stake 1,130% to 123 shares ($26,000).

  6. Wall Street Zen downgrades MBRX

    Cut its rating from 'sell' to 'strong sell' in a research note

  7. Q1 2026 institutional accumulation

    Goldman Sachs lifted its position 32.3% to 242,732 shares ($55.0M). Jane Street increased 38.9% to 20,716 shares ($4.7M). Woodline Partners grew 40.0% to 8,300 shares ($1.88M). Jones Financial raised 46.1%. Empowered Funds added 16.1%. Geneos Wealth grew 416.0%. Western Wealth opened a new $25,000 stake.

  8. Jane Street Group discloses new MBRX position

    Acquired 22,550 shares valued at approximately $75,000 during Q4 2025, per SEC filing, representing about 1.11% of the company

  9. Q4 2025 13F filings

    Activest Wealth Management raised its STERIS stake 423.8% to 110 shares ($28,000), and Measured Wealth Private Client Group opened a new position valued at about $28,000.

Stories mentioning Jane Street Group LLC 8

Healthcare medical devices Neutral 5

STERIS Institutional Ownership Hits 94.69% on 32.3% Goldman Boost

A wave of institutional accumulation in STERIS plc — including a 32.3% Goldman Sachs position increase and a new $1.03 million Stoneridge stake in Q2 2026 — signals confidence in the medical equipment provider's infection-prevention franchise. With institutions now holding 94.69% of shares and the company maintaining a 0.23 debt-to-equity ratio, STERIS appears positioned to absorb hospital capital-expenditure cycles. A modest June insider sale by director Richard C. Breeden at $209.51 is a minor contrarian signal in an otherwise bullish institutional pattern.

2 sources
Finance markets Neutral 5

Goldman Sachs Ups STERIS 32.3% as Institutions Own 94.69%

STERIS plc's latest 13F disclosures show a broad institutional accumulation wave: Goldman Sachs raised its stake 32.3% to 242,732 shares ($55M) in Q1, and Stoneridge Investment Partners opened a new $1.03M position in Q2. With 94.69% of the float owned by institutions and a director selling $310K of stock in June, the signals are mixed. Conservative leverage (debt-to-equity 0.23) and a 1.35 quick ratio support the long case.

2 sources

Source: tickerreport.com · dailypolitical.com

Finance earnings Neutral 5

MBRX Down 97% to $0.57 Despite EPS Beat: $22 Target Stale?

Moleculin Biotech shares rose 9.6% to $0.57 after a narrower-than-expected Q2 loss, yet the stock remains down roughly 97% from its 12-month high, with analysts' average $22.00 target detached from reality. The real signal for traders is a 2.3x volume surge, a beta of 1.83, and thin 15.52% institutional ownership.

2 sources
Biotech funding Neutral 5

Moleculin's $4.06M Market Cap vs ($1.40) EPS: Pipeline Survival?

Clinical-stage Moleculin Biotech is now valued at just $4.06 million after a 97% collapse from its 52-week high, raising existential questions about its ability to fund development of therapies for resistant tumors and viral infections. The EPS 'beat' of ($1.40) versus ($1.55) is a paper figure — no revenue, cash balance, or clinical milestone accompanied the report.

2 sources

Source: dailypolitical.com · themarketsdaily.com

Finance earnings Neutral 5

Smith-Midland Posts $0.26 EPS, $23.36M Revenue; Shares Rise 1.7%

Smith-Midland's latest quarterly results show a profitable small-cap with an almost 20% return on equity and very low leverage, even as the stock trades about 35% below its 52-week high. The $0.26 EPS and $23.36 million revenue figure, combined with rising institutional holdings, make it a watch item for value-oriented small-cap investors. However, the stock remains below its 50-day and 200-day moving averages, keeping the technical picture cautious.

2 sources

Source: MarketBeat · themarketsdaily.com

Healthcare market trends Neutral 5

ENSC Shorts Up 619.9% at $0.30; FCUV Revenue $0.05M

Ensysce Biosciences short interest soared 619.9% to 364,278 shares as its stock trades at $0.30, while Focus Universal posted just $0.05M in quarterly revenue. The data highlights severe financial fragility across two small healthcare and device innovators.

2 sources
Retail e commerce Neutral 5

Retail Partner Cardlytics Sees CEO Sell $70K as Stock Tanks 87% to $4.37

Cardlytics, whose platform powers cashback offers inside banking apps for major retailers, is under financial strain—its stock has plummeted to $4.37 and the CEO has unloaded shares. The company’s tiny $25M market cap and negative earnings put its future in doubt, directly affecting retail brands that depend on it for consumer acquisition and loyalty campaigns.

2 sources

Source: dailypolitical.com · themarketsdaily.com